Global Haemophilia Treatment Market Report and Forecast 2024-2032

Global Haemophilia Treatment Market Outlook

The global haemophilia treatment market size reached a value of about USD 14.84 billion in 2023. The market is expected to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to attain a value of USD 28.44 billion by 2032, driven by the rising prevalence of increased rapid advancement in the industry and increasing awareness among people.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Haemophilia Treatment Market: Introduction and Overview

Haemophilia is a condition in which the blood clotting does not take place in the human body. The amount of blood clotting depends on the level of severity of the condition in the patient. Haemophilia happens when a human body lacks of blood clotting proteins hence, unable to clot the blood. Symptoms of haemophilia include bleeding in different parts of the body which may occur occasionally and spontaneously.

The market is growing rapidly and is expected to continue growing in the coming years as well. The major role is played by the governments and organizations that are continuously putting efforts in spreading awareness about haemophilia treatment globally. Also, the increased rate of research and development to determine the appropriate and effective treatments and therapies for the condition is among the major factors that are aiding the rapid growth of the global haemophilia market.

North America has been the leading region in the industry and contributed to a significant market share. It is expected to be doing the same for the forecast period as well. The reason behind North America being the leader of the treatment market is the rapid advancing of the technologies that are used to develop advanced products for the patients. The increasing prevalence of haemophilia is also a major reason for the rise of the global haemophilia treatment market share in North America.

Market Segmentations:

The haemophilia treatment market can be segmented into different categories such as disease type, product type, therapy type, treatment channel, distribution channel, and region.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diseases Type

• Haemophilia A

• Haemophilia B

• Haemophilia C

• Others

Market Breakup by Product Type

• Recombinant Coagulation Factor Concentrate

• Plasma Derived Coagulation Factor Concentrate

• Desmopressin

• Antifibrinolytics Agents

Market Breakup by Therapy Type

• Replacement Therapy

• Gene Therapy

• Immune Tolerance Induction Therapy

• Others

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

• Others

Global Haemophilia Treatment Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Haemophilia Treatment Market: Treatment Ladscape

There are significant research and developments going on in the market. Some of them have not been approved yet and some of them are in use already. However, the market is continuously developing and growing. The most recent key developments that have been introduced in the market to cure the haemophilia include the use of concentrates of plasma derived factors in the treatment. Liquid component of the blood is called plasma. It is commonly pale-yellow in colour and contains proteins like albumin, clotting factors, and antibodies. These plasma proteins are used in the composition of various factor concentrate therapeutic solutions. The human blood has to undergo several processes to split into different components such as clotting factors.

Other key drugs used in the treatment market are as follows:

• HEMLIBRA

Instead of directly replacing the lost clotting factor VIII, HEMLIBRA functions to replace factor VIII functions. It can be applied to haemophilia A patients to either stop or lessen the frequency of bleeding episodes. This can be administered by skin injections.

• DDAVP

The drug DDAVP and Stimate resemble a hormone that the body naturally produces. Factor VIII is kept in the bodily tissues and is released by the drugs. This can help people with mild and moderate haemophilia by self-increasing the level of factor VIII.

• Amicar

This is a drug that could be taken directly via mouth or in veins through injections. It could be in the form of a pill or a liquid. This drug helps in developing a stronger blood clot that does not break down easily.

Competitive landscape:

This report gives a detailed analysis of the following key players in the global haemophilia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds. The key players in the market are as follows:

• Novo Nordisk A/S

• Pfizer Inc

• Bayer AG

• Biogen Inc.

• CSL Behring

• Grifols SA

• Octapharma AG

• Kedrion S.p.A Ferring Pharmaceuticals Inc.

• F. Hoffmann-La Roche Ltd.

Key Highlights of the Report

Haemophilia Treatment Market Report Snapshots

Haemophilia Treatment Market Size

Haemophilia Treatment Companies